Health care stocks were declining premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV) slightly lower and the iShares Biotechnology ETF (IBB) down 0.2%.
Coherus BioSciences (CHRS) shares were up past 69% after the company said it has agreed to divest its biosimilar drug Udenyca, which is based on Amgen's (AMGN) Neulasta, to Intas Pharmaceuticals for up to $558.4 million.
HUTCHMED (HCM) stock was over 3% higher after the company and Innovent Biologics said the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.
Novo Nordisk's (NVO) India-based executives have proposed moving up the launch of the weight-loss drug Wegovy in the country to 2025, instead of 2026 as planned, due to concerns about falling behind Eli Lilly's (LLY) Mounjaro, Reuters reported, citing two sources familiar with the matter. Novo Nordisk shares were over 2% higher premarket.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。